Business Wire

NIPPON-SHOKUBAI

20.9.2022 15:31:37 CEST | Business Wire | Press release

Share
NIPPON SHOKUBAI: Investment in a Manufacturer of Lithium Salt as the Electrolyte for Lithium-ion Battery in China

NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter “Nippon Shokubai”) (TOKYO:4114) aims to expand our LiFSI* business in China, the biggest market of lithium-ion batteries (hereinafter “LIB”). We hereby announce that, as part of this business expansion, we have reached agreement on investment in Hunan Fluopont New Materials Co., Ltd. (hereinafter “Hunan Fluopont”), a subsidiary of Shenzhen CAPCHEM Technology Co. Ltd. (hereinafter “Capchem”), who is currently making efforts to establish production facilities to enter LiFSI business.
*Lithium bis (fluorosulfonyl) imide (Product name: IONEL™), a lithium salt as the advanced electrolyte which was commercialized first in the world by Nippon Shokubai.

1. Background of the alliance

With a rising awareness of environmental issues in recent years, there is a high demand for electric vehicle (EV), which is an industry-leading product of energy-saving and low-pollution next-generation vehicles, and this has led to the rapid expansion of the LIB market for EV. Because using LiFSI as an electrolyte in LIB for EV significantly improves the battery’s cyclic and rate performance as well as storing stability over a wide temperature range from low to high temperatures, LiFSI has been adapted not only as an additive, but also as a main ingredient of the electrolyte. As this has led to a surge in LiFSI demand particularly in Asia and Europe, early business expansion to China, the world’s biggest LIB market for vehicles has been a key for us to make a big leap in our IONEL™ business.

2. Purpose of the alliance

Under these circumstances, in order to acquire high-profile customers and early establish a cost-competitive manufacturing and sales structure in China with the largest LIB demand, we have decided to form an alliance with Capchem, a major electrolyte solution manufacturer, and Toyota Tsusho Corporation (Headquarters: Nagoya, Japan, President: Ichiro Kashitani, hereinafter “Toyota Tsusho”), who is Toyota Group’s general trading company. The investment will be made by Toyota Tsusho (Shanghai) Co., Ltd. (hereinafter “Toyotsu Shanghai”). This will allow us to combine our state-of-the-art LiFSI production technologies, quality control capability, and intellectual properties with Hunan Fluopont’s cost-competitiveness, location, material procurement capability, production system, and existing technologies, and Capchem’s LiFSI purchasing capability supported by their top-level supply capacity of electrolyte solutions, as well as Toyota Tsusho’s world-wide sales network encompassing China. Through this alliance, we will aim to accelerate our IONEL™ business in the electrolyte market.

LiFSI is known as a difficult substance to purify to a high degree, which is only achieved by advanced know-how for its production and quality management. Using our unique production technology that we have nurtured over the years, in 2013, we succeeded in the development of an industrial production process of highly-pure LiFSI with few solvents and by-products, exhibiting stable electrochemical properties, for the first time in the world. Our product has been adopted and certified as the electrolyte by many LIB manufacturers inside and outside Japan with a wide variety of applications including vehicle, consumer-use, and stationary batteries.
(For details of LiFSI, please refer to our website: https://www.shokubai.co.jp/en/lp/ionel/)

Capchem is the world’s second largest manufacturer of electrolyte solution for LIB with five production sites in China, and has a track record of providing its products to major LIB manufacturers. Their business includes not only manufacturing of electrolyte solution, but also in-house material production of solvent, electrolyte, additive, which enables them to offer electrolyte solution with price competitiveness and high quality.

Toyota Tsusho is looking to expand their LiFSI sales beyond China to electrolyte solution manufactures in Japan, Asia, and Europe to meet the surging demand in the electrolyte solution and electrolyte markets.

Hunan Fluopont started its production in the second half of FY2022 with the first unit (production capacity 1,200t/y). It is planned to be expanded in stages to satisfy the rapidly increasing market demand, aiming to have annual production capacity of 12,000 ton/y in 2025.

3. Investment overview

Nippon Shokubai and Toyotsu Shanghai will invest in the following company.

(1)

 

Company name

 

 

Hunan Fluopont New Materials Co., Ltd.

(2)

 

Location

 

 

Shigu District, Hengyang, Hunan, China

(3)

 

Amount invested (third-party allocation of shares)

 

 

Nippon Shokubai: 201,769,912 RMB (4.04 billion JPY)

 

 

Toyotsu Shanghai: 29,203,539 renminbi (580 million JPY)

 

 

[Assumed exchange rate: 20 JPY/RMB]

(4)

 

Shareholders

 

 

Capchem: 51.19%

 

 

Nippon Shokubai: 38.0%

 

 

Toyotsu Shanghai: 5.5%

 

 

Changsha ShinLian Huayuan Alternative Energy Partnership Enterprise (shareholding association by executive employees of Hunan Fluopont): 5.31%

(5)

 

Representative

 

 

Shu Ping Ai

(6)

 

Businesses

 

 

Manufacturing and sales of electrolyte LiFSI for LIB

(7)

 

Production capacity

 

 

Current: 1,200t/year in the second half of FY2022

 

 

Plan: 12,000t/year in FY2025

Related information

Profile of Shenzhen CAPCHEM Technology Co. Ltd.

Company Name

Shenzhen CAPCHEM Technology Co. Ltd.

Location

Capchem Plaza, Changye Road, Pingshan District, Shenzhen, Guangdong Province, China.

Establishment

1996

Capital

410 million RMB (8.2 billion JPY) (as of end of 2021)

Total assets

223.3 billion JPY (as of end of 2021)

Sales

139 billion JPY (FY2021)

Operating profit

30.8 billion JPY (FY2021)

Business overview

Lithium battery chemicals, organic fluorine chemicals, capacitor chemicals and semiconductor chemicals. For lithium-ion battery electrolytes in mass production at five production sites in China and several other production sites under construction in China and Poland.

Website

https://en.capchem.com/

Profile of Toyota Tsusho Corporation

Company Name

Toyota Tsusho Corporation

Location

9-8, Meieki 4-chome, Nakamura-ku, Nagoya 450-8575 Japan

Establishment

1948

Capital

64.9 billion yen (as of end of March 2022)

Total assets

6,143.1 billion yen (as of end of March 2022)

Sales

8,028 billion yen (FY 2021)

Operating profit

294.1 billion yen (FY 2021)

Business overview

As a general trading company of Toyota Group, the company has expanded its business with a focus on exports of vehicles and automobile production support. The company has seven business fields (Metals, Global Parts & Logistics, Automotive, Machinery, Energy & Project , Chemicals & Electronics, , Food & Consumer Services, and Africa). and focuses on three core businesses, Mobility business that contributes to future convenient society, Resources & Environment business that contributes to sustainable society and Life & Community business that contributes to comfortable & healthy society. Around 65,000 Group employees are engaged in business in about 130 countries.

Website

https://www.toyota-tsusho.com/english/

Profile of Toyotsu Shanghai

Company Name

TOYOTA TSUSHO (SHANGHAI) CO.,LTD.

Location

1717 Nanjing West Road, Jinganqu, Shanghai, China

Establishment

1995

Capital

33.18 million RMB (660 million JPY) (as of end of March 2022)

Business overview

The company mainly operates trading businesses with a wide variety of business units including Metal, Global and Logistics, Chemical Products and Electronics, Mechanical and Energy Plant Project, Food and Household Items, and East Asia Next Mobility Promotion Project.

About NIPPON SHOKUBAI: Since 1941, Nippon Shokubai has grown up its business with unique catalyst technology. Nippon Shokubai has supplied, for example, ethylene oxide and acrylic acid. Among all, our production capacity of superabsorbent polymers is the largest in the world (according to Nippon Shokubai research). We are currently focused on the Solutions Business, and IONEL (LiFSI) mentioned on this announcement plays a key role in accelerating the business. Nippon Shokubai is a global chemical company operating under its corporate mission “TechnoAmenity - Providing prosperity and comfort to people and society, with our unique technology.”
https://www.shokubai.co.jp/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006154/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Global udvider sin juridiske virksomhed i Pakistan med et nyt medlemsfirma2.10.2026 22:36:00 CEST | Pressemeddelelse

Andersen Global styrker sin juridiske tilstedeværelse i Pakistan, idet Samdani & Qureshi, der har været samarbejdspartner siden 2021, skifter navn til Andersen Legal in Pakistan og bliver den seneste medlemsvirksomhed, der slutter sig til organisationen. Andersen Legal in Pakistan har hovedkontor i Islamabad og rådgiver både indenlandske og internationale klienter, herunder virksomheder, investorer, finansielle institutioner, offentlige enheder, udviklingsorganisationer og privatpersoner, om juridiske, kommercielle og regulatoriske forhold. Firmaet arbejder også med voldgift og tvistbilæggelse og rådgiver om komplekse transaktioner, investeringer, finansiering, projekter og tvister i Pakistan og på tværs af landegrænser. "Vores tilgang bygger på stærkt engagement fra ledelsen, klar kommunikation og disciplineret analyse med fokus på at levere rådgivning, som vores klienter kan omsætte til handling," sagde Nudrat Ejaz Piracha, partner hos Andersen Legal in Pakistan. "Ved at blive en del

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press release

Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release

Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release

Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye